Download PDF
Indian Journal of Neurotrauma 2008; 05(01): 27-33
DOI: 10.1016/S0973-0508(08)80025-1
Original Article
Thieme Medical and Scientific Publishers Private Ltd.

Randomized controlled trial of magnesium sulphate in severe closed traumatic brain injury

SS Dhandapani
,
Aditya Gupta
,
S Vivekanandhan
*   Department of Neurobiochemistry, Neurosciences centre All India Institute of Medical Sciences, New Delhi
,
BS Sharma
,
AK Mahapatra
› Author Affiliations
Subject Editor:
Further Information

Publication History

Publication Date:
05 April 2017 (online)

  PDF Download  Permissions and Reprints

Abstract

Magnesium decline is likely to play an important role in the pathogenesis of Traumatic Brain Injury (TBI). This study was undertaken to test the therapeutic efficacy and safety of parenterally administered Magnesium sulphate (MgSO4) in patients of severe closed TBI. Adult patients admitted within 12 hours of closed TBI with Glasgow coma score 5 to 8 fulfilling eligibility criteria were randomized to two groups, one group receiving ‘standard care’ and the other, MgSO4 in addition as per the Pritchard regimen. The outcome measures were Glasgow outcome scale at 3 months and other relevant clinical parameters. Seventy patients were randomized after obtaining informed consent, and 30 in each group remained in the study till 3 months. Favorable outcome was observed in 22 out of 30 patients (73.3%) who had received MgSO4, as compared with 12 out of 30 (40%) in control group. Univariate analysis revealed an odds ratio (OR) of 4.13 (95% CI 1.39–12.27) and the P value was 0.009. In the logistic regression analysis, the adj. OR was 4.24 (95% CI 1.1–16.36) and the P value was 0.036. The secondary outcomes analyzed in MgSO4 group showed significant difference with respect to intra-operative brain swelling at the end of surgical decompression and mortality at 1 month. No significant adverse effects were observed. Parenteral MgSO4 appears to have some favorable influence on mortality and intra-operative brain swelling without any significant adverse effects.

Keywords

Severe traumatic brain injury - Magnesium sulphate - Pritchard regimen - Outcome
 

  • References

  • 1 Ghajar J. Traumatic brain injury. Lancet 356 2000; 923-929
    CrossrefPubMedGoogle Scholar
  • 2 Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in Traumatic Brain Injury. J Exp Pharm Phy 28 2001; 919-921
    PubMedGoogle Scholar
  • 3 Reilly PL. Brain injury: the pathophysiology of the first hours. ‘Talk and Die’ revisited. J Clin Neurosci 08 2001; 398-403
    CrossrefPubMedGoogle Scholar
  • 4 McIntosh TK, Juhler M, Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury. J Neurotrauma 19 1998; 731-769
    PubMedGoogle Scholar
  • 5 van den Heuvel C, Vink R. The role of magnesium in traumatic brain injury. Clin Calcium 14 2004; 9-14
    PubMedGoogle Scholar
  • 6 Heath DL, Vink R. Neuroprotective effect of MgSO4 and MgCl2 in closed head injury: A comparative phosphorus NMR study. J Neurotrauma 15 1998; 183-189
    CrossrefPubMedGoogle Scholar
  • 7 Heath DL, Vink R. Optimisation of magnesium therapy following severe diffuse axonal brain injury in rats. J Pharmacol Exp Ther 288 1999; 180-186
    PubMedGoogle Scholar
  • 8 Smith DH, Okiyama K, Gennarelli TA, McIntosh TK. Magnesium treatment attenuates cognitive dysfunction following experimental brain injury. Neurosci Lett 157 1993; 211-214
    CrossrefPubMedGoogle Scholar
  • 9 Pritchard JA, Cunningham FG, Pritchard SA. The Parkland memorial hospital protocol for treatment of Eclampsia: Evaluation of 245 cases. Am J Obstet Gynecol 148 1984; 952-963
    PubMedGoogle Scholar
  • 10 Marshall LF, Marshall SB, Klauber MR. A new classification of head injury based on computerized tomography. J Neurosurg 75 Suppl 1991; S14-S20
    CrossrefPubMedGoogle Scholar
  • 11 Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet 01 1975; 480-484
    PubMedGoogle Scholar
  • 12 Graham DI, Gennarelli A. Trauma. In: Graham DI, Lantos PL. eds. Greenfield’s Neuropathology. 6th. ed. 1997. Arnold; United Kingdom: 197-203
    Google Scholar
  • 13 Bullock MR, Lyeth BG, Muizelaar JP. Current status of neuroprotection trials for traumatic brain injury: Lessons learned from animal models and clinical studies. Neurosurgery 45 1999; 207-220
    CrossrefPubMedGoogle Scholar
  • 14 Graham DI, Adams JH, Doyle D. Ischemic brain damage in fatal non-missile head injuries. J Neurol Sci 39 1978; 213-234
    CrossrefPubMedGoogle Scholar
  • 15 Fox C, Ramsoomair D, Carter C. Magnesium: Its proven and potential clinical significance. South Med J 94 2001; 1195-1201
    CrossrefPubMedGoogle Scholar
  • 16 Johnson JW, Ascher P. Voltage-dependent block by intracellular Mg2+ of N-methyl-D-aspartate-activated channels. Biophys J 57 1990; 1085-1090
    CrossrefPubMedGoogle Scholar
  • 17 Lin JY, Chung SY, Lin MC, Cheng FC. Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique. Life Sci 71 2002; 803-811
    CrossrefPubMedGoogle Scholar
  • 18 Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J 108 1984; 188-193
    CrossrefPubMedGoogle Scholar
  • 19 Okiyama K, Smith DH, Gennarelli TA, Simon RP, Leach M, McIntosh TK. The Sodium channel blocker and glutamate release inhibitor BW1003C87 and Magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem 64 1995; 802-809
    PubMedGoogle Scholar
  • 20 Vink R, McIntosh TK, Demediuk P, Faden AI. Decrease in total and free magnesium concentration following traumatic brain injury in rats. Biochem Bioph Res Comm 149 1987; 594-599
    CrossrefPubMedGoogle Scholar
  • 21 Vink R, McIntosh TK, Demediuk P, Weiner MW. Decline in intracellular free magnesium is associated with irreversible brain injury following brain trauma. J Biol Chem 263 1988; 757-761
    PubMedGoogle Scholar
  • 22 Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. Hypomagnesemia and hypophosphatemia at admission in patients with severe head injury. Crit Care Med 28 2000; 2022-2025
    CrossrefPubMedGoogle Scholar
  • 23 Bareyre FM, Saatman KE, Helfaer MA. et al Alterations in ionized and total blood magnesium after experimental traumatic brain injury: relationship to neurobehavioral outcome and neuroprotective efficacy of magnesium chloride. J Neurochem 73 1999; 271-280
    PubMedGoogle Scholar
  • 24 Memon ZI, Altura BT, Benjamin JL, Cracco RQ, Altura BM. Predictive value of serum ionized but not total magnesium levels in head injuries. Scand J Clin Lab Invest 55 1995; 671-677
    CrossrefPubMedGoogle Scholar
  • 25 Andersen BJ, Marmarou A. Post-traumatic selective stimulation of glycolysis. Brain Res 585 1992; 184-189
    CrossrefPubMedGoogle Scholar
  • 26 Kuroda Y, Inglis FM, Miller JD, McCulloch J, Graham DI, Bullock R. Transient glucose hypermetabolism after acute subdural hematoma in the rat. J Neurosurg 76 1992; 471-477
    CrossrefPubMedGoogle Scholar
  • 27 McIntosh TK, Faden AI, Yamakami I, Vink R. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 31P magnetic resonance spectroscopy and other studies. J Neurotrauma 05 1988; 17-31
    CrossrefPubMedGoogle Scholar
  • 28 Bareyre FM, Saatman KE, Raghupathi R, McIntosh TK. Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats. J Neurotrauma 17 2000; 1029-1039
    CrossrefPubMedGoogle Scholar
  • 29 Heath DL, Vink R. Delayed therapy with magnesium upto 24h following traumatic brain injury improves motor outcome. J Neurosurg 90 1999; 504-509
    CrossrefPubMedGoogle Scholar
  • 30 Tandon PN. Acute Subdural Haematoma: A Reappraisal. Neurol India 49 2001; 3-10
    PubMedGoogle Scholar
  • 31 Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 129 2004; 1021-1029
    CrossrefPubMedGoogle Scholar
  • 32 Chi OZ, Pollak P, Weiss HR. Effects of magnesium sulfate and nifedipine on regional cerebral blood flow during middle cerebral artery ligation in the rat. Arch Int Pharmacodyn Ther 304 1990; 196-205
    PubMedGoogle Scholar
  • 33 van den Bergh WM, Algra A, van Kooten F. et al MASH Study Group. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 36 2005; 1011-1015
    CrossrefPubMedGoogle Scholar
  • 34 Lucas MJ, Leveno KJ, Cunningham FG. A comparison of Magnesium sulphate with phenytoin for the prevention of eclampsia. N Eng J Med 333 1995; 201-205
    CrossrefPubMedGoogle Scholar
  • 35 The Magpie trial collaborative group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomized placebo — controlled trial. Lancet 359 2002; 1877-1890
    CrossrefPubMedGoogle Scholar
  • 36 Belfort MA, Moise Jr KJ. Effect of magnesium sulphate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study. Am J Obstet Gynecol 167 1992; 661-666
    CrossrefPubMedGoogle Scholar
  • 37 Vanden Veyyer IB, Belfort MA, Rowe TF, Moise KJ. Cerebral vasopasm in eclampsia: Transcranial Doppler ultrasound findings. J Matern Fetal Med 03 1994; 9-13
    PubMedGoogle Scholar
  • 38 Canavero S, Bonicalzi V, Narcisi P. Safety of magnesium-lidocaine combination for severe head injury: the Turin lidomag pilot study. Surg Neurol 60 2003; 165-169
    CrossrefPubMedGoogle Scholar
  • 39 Braakman R, Gelpke GJ, Habbema JD, Maas AI, Minderhoud JM. Systematic selection of prognostic features in patients with severe head injury. Neurosurgery 06 1980; 362-370
    CrossrefPubMedGoogle Scholar
  • 40 Sibai BM, Graham JM, McCubbin JH. A comparison of intravenous and intramuscular magnesium sulfate regimens in preeclampsia. Am J Obstet Gynecol 15 1984; 150 728-33.
    PubMedGoogle Scholar